Medical Doctor Program year 2019 Source: CMS Open Payments, 2026 publication

Athena Phan

Dermatology Montgomery, AL Medical Doctor

NPI 1386793925 CMS profile 972182

202 Mitylene Park Dr, Montgomery, AL 36117

Open in the dashboard

General payments

$39

3 records reported · program year 2019

Research payments

$0

Paid to them · None reported · program year 2019

Ownership & investment interest

$0

None reported

Through program year 2019, Athena Phan of Montgomery, AL is reported in the CMS Open Payments database as having received $39 across 3 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 4th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2019 General $39 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Athena Phan
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Athena Phan were reported at $0. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Athena Phan Dermatology median Middle half National median
2019 $39 $454 $129–$1,240 $163
2020 $0 $235 $81–$756 $114
2021 $0 $377 $108–$1,108 $132
2022 $0 $514 $143–$1,391 $149
2023 $0 $607 $159–$1,674 $160
2024 $0 $751 $204–$1,903 $164
2025 $0 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program year 2019
  1. Pfizer Inc. $24 2 payments
  2. Lilly USA, LLC $14 1 payment

Every payment, record by record

What the payments were for General payments · program year 2019
  1. Food and Beverage $39 3 payments
Products named General payments · program year 2019
  1. EUCRISA $24 2 payments
  2. TALTZ $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

2,352

Median for Dermatology: 534

Drug cost

$98,451

Median for Dermatology: $67,151

Branded share of claims

2.3%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Metronidazole Generic 439 $25,130
Doxycycline Ir-Dr Doxycycline Monohydrate Brand 12 $11,762
Fluorouracil Generic 139 $10,814
Ketoconazole Generic 319 $8,422
Azelaic Acid Generic 40 $8,396
Triamcinolone Acetonide Generic 512 $4,226
Clobetasol Propionate Generic 83 $4,189
Ammonium Lactate Generic 186 $4,126
Doxycycline Monohydrate Generic 95 $3,676
Fluocinonide Generic 61 $3,066

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$534,918

Of which drugs: $153

Medicare patients

1,259

Average age 76

Services billed

18,546

749 women, 510 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Ischemic heart disease 33%
Diabetes 25%
Chronic kidney disease 19%
Osteoporosis 17%
Atrial fibrillation 16%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 35 216 $153

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

3 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2019

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record